Keywords: 1st, head-to-head, kytril/zofran, study, glaxo, zofran, ondansetron
1ST HEAD-TO-HEAD KYTRIL/ZOFRAN STUDY
Article | 11 July 1994
Glaxo's Zofran (ondansetron) and SmithKline Beecham's Kytril (granisetron) in injectable form are equally effective in controlling chemotherapy-induced nausea and vomiting ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
